MapLight Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for MapLight Therapeutics, Inc. (MPLT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are MPLT insiders buying or selling?
In the last 12 months, MapLight Therapeutics, Inc. insiders reported 7 open-market purchases ($174.9M) and 33 sales ($29.2M) — net buying of $145.8M. Since October 2025, Trabud has recorded 40 Form 4 filings for MPLT: 7 buys ($174.9M) and 33 sells ($29.2M).
Source: SEC EDGAR Form 4
Key Statistics (October 2025 – Sep 18, 2026)
Total Form 4 filings
40
SEC EDGAR
Insider filers
13
Insider buys (7)
$174.9M
Insider sells (33)
$29.2M
Insider sentiment
Net buyingNet insider flow of $145.8M in net buying since October 2025, and $145.8M in net buying over the last 12 months. 3 insider buys in the last 90 days.
Recent MPLT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Kristopher Hanson | General Counsel | Sale | 16.5K | $11.67 | $192.7K | SEC ↗ |
| Aug 18, 2026 | Catalyst4, Inc. | 10% Owner | Purchase | 4.4M | $11.38 | $50.1M | SEC ↗ |
| Aug 5, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 22.1K | $12.54 | $276.9K | SEC ↗ |
| Jul 30, 2026 | Catalyst4, Inc. | 10% Owner | Purchase | 1.2M | $12.66 | $15.3M | SEC ↗ |
| Jul 29, 2026 | Troy Cox | Director | Purchase | 15.6K | $9.52 | $148.7K | SEC ↗ |
| Jul 20, 2026 | Jonathan Gillis | CAO and Interim CFO | Sale | 37.0K | $37.12 | $1.4M | SEC ↗ |
| Jul 20, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale | 36.3K | $37.09 | $1.3M | SEC ↗ |
| Jul 18, 2026 | Christopher A. Kroeger | Chief Executive Officer | Sale | 147.6K | $36.87 | $5.4M | SEC ↗ |
| Jul 18, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 18.3K | $36.88 | $673.6K | SEC ↗ |
| Jul 18, 2026 | Kristopher Hanson | General Counsel | Sale | 16.5K | $36.82 | $607.9K | SEC ↗ |
| Jul 18, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale | 47.2K | $36.78 | $1.7M | SEC ↗ |
| May 19, 2026 | Christopher A. Kroeger | Chief Executive Officer | Sale | 118.2K | $27.19 | $3.2M | SEC ↗ |
| May 12, 2026 | Kristopher Hanson | General Counsel | Sale | 13.9K | $30.13 | $419.3K | SEC ↗ |
| May 12, 2026 | Christopher A. Kroeger | Chief Executive Officer | Sale | 68.5K | $28.47 | $1.9M | SEC ↗ |
| May 12, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale | 4.4K | $28.54 | $126.6K | SEC ↗ |
| May 12, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 721 | $28.28 | $20.4K | SEC ↗ |
| May 7, 2026 | Vishwas Setia | Chief Financial Officer | Sale | 36.4K | $28.17 | $1.0M | SEC ↗ |
| May 7, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale | 50.3K | $28.39 | $1.4M | SEC ↗ |
| May 7, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 51.7K | $28.40 | $1.5M | SEC ↗ |
| May 7, 2026 | Kristopher Hanson | General Counsel | Sale | 13.9K | $27.89 | $388.2K | SEC ↗ |
| May 7, 2026 | Christopher A. Kroeger | Chief Executive Officer | Sale | 49.7K | $28.39 | $1.4M | SEC ↗ |
| Apr 29, 2026 | Jonathan Gillis | CAAO and PAO | Sale | 69.8K | $29.89 | $2.1M | SEC ↗ |
| Apr 29, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale | 45.4K | $29.66 | $1.3M | SEC ↗ |
| Apr 17, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale | 3.3K | $26.61 | $88.2K | SEC ↗ |
| Apr 17, 2026 | Jonathan Gillis | CAAO and PAO | Sale | 3.6K | $26.61 | $95.5K | SEC ↗ |
Showing the 25 most recent of 40 Form 4 filings for MapLight Therapeutics, Inc..
Most active MPLT insiders
- Robert C. Malenka6 filings
- Christopher A. Kroeger5 filings
- James Woodruff Lillie5 filings
- Kristopher Hanson5 filings
- Erin Pennock Foff4 filings
Ask anything about MPLT insider activity
Use Trabud's AI agent to query MapLight Therapeutics, Inc.'s Form 4 history in plain English — "Show me MPLT CEO purchases this year" or compare it against any other ticker.
Open the AI agentMPLT insider trading FAQ
Are MapLight Therapeutics, Inc. insiders buying or selling?
In the last 12 months, MapLight Therapeutics, Inc. insiders reported 7 open-market purchases ($174.9M) and 33 sales ($29.2M) — net buying of $145.8M. Since October 2025, Trabud has recorded 40 Form 4 filings for MPLT: 7 buys ($174.9M) and 33 sells ($29.2M). Over the full record that is net buying of $145.8M.
How many insiders trade MPLT stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for MapLight Therapeutics, Inc.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get MPLT insider trading data?
All MPLT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.